Security Snapshot

XERIS BIOPHARMA HOLDINGS INC - NOTE 8.000% 7/1 Institutional Ownership

CUSIP: 98422EAB9

13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

2

Principal

$33,574,000

Price (% of par)

204.56%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 2 signals
Principal change
$0
Number of holders
2
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported market price (% of par)
204.56%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 98422EAB9 - XERIS BIOPHARMA HOLDINGS INC - NOTE 8.000% 7/1 is tracked under CUSIP 98422EAB9.
  • 2 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 2 to 2 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $89,025,941 to $68,666,495.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 2 institutions filings for Q1 2026.

Open SEC evidence

Security key

98422EAB9

Latest holder period

Q1 2026

13F holders

2

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 2 institutional investors reported holding $33,574,000 in principal (par value) of XERIS BIOPHARMA HOLDINGS INC - NOTE 8.000% 7/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
5
Latest
Q1 2026
Rows shown
1-5 of 5
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q1 $33,574,000 $68,666,495 204.56% 2
2025 Q4 $33,574,000 $89,025,941 265.45% 2
2025 Q3 $33,574,000 $90,779,780 +$10,992,544 271.25% 2
2025 Q2 $33,574,000 $56,929,471 -$434,324 169.38% 2
2025 Q1 $33,574,000 $63,951,074 +$63,951,074 189.86% 3
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .